3/23
09:03 am
mnov
MediciNova (MNOV) had its "buy" rating reaffirmed by Maxim Group. They now have a $6.00 price target on the stock.
Medium
Report
MediciNova (MNOV) had its "buy" rating reaffirmed by Maxim Group. They now have a $6.00 price target on the stock.
3/19
06:20 am
mnov
MediciNova (MNOV) was upgraded by Zacks Research to "hold".
Low
Report
MediciNova (MNOV) was upgraded by Zacks Research to "hold".
3/16
08:03 am
mnov
MediciNova (MNOV) is now covered by HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.
Medium
Report
MediciNova (MNOV) is now covered by HC Wainwright. They set a "buy" rating and a $10.00 price target on the stock.
3/16
07:00 am
mnov
MediciNova to Participate at the 38th Annual ROTH Conference
High
Report
MediciNova to Participate at the 38th Annual ROTH Conference
2/20
06:46 am
mnov
MediciNova: Q4 Earnings Snapshot [Yahoo! Finance]
Low
Report
MediciNova: Q4 Earnings Snapshot [Yahoo! Finance]
1/30
08:03 am
mnov
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
Low
Report
MediciNova (NASDAQ:MNOV) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $9.00 price target on the stock.
1/30
02:52 am
mnov
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients [Yahoo! Finance]
Medium
Report
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients [Yahoo! Finance]
1/29
06:00 pm
mnov
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
Low
Report
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients
1/7
07:11 am
mnov
MediciNova (NASDAQ:MNOV) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.
Low
Report
MediciNova (NASDAQ:MNOV) was upgraded by analysts at Lucid Cap Mkts to a "strong-buy" rating.
1/6
09:00 am
mnov
2026 New Year’s Greetings from the CEO
Low
Report
2026 New Year’s Greetings from the CEO